Adam Taich, Chief Financial Officer of 10x Genomics, Inc. (NASDAQ:TXG), sold 15,098 shares of the company’s Class A Common Stock on May 22, 2026. The transaction totaled $369,017, with shares sold at a price of $24.4415 each. The sale occurred as shares trade near their 52-week high of $26.45, following a remarkable 197% gain over the past year.
The sale was conducted to cover tax withholding obligations in connection with the vesting of restricted stock units. Following this transaction, Mr. Taich directly holds 379,898 shares of 10x Genomics Class A Common Stock. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value. For deeper insights into TXG’s valuation and financial health, investors can access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, 10X Genomics has been in the spotlight following several key developments. William Blair upgraded the company’s stock rating to Outperform, emphasizing its significant role in AI-driven drug discovery, and noted the firm’s consistent performance with five consecutive top-line beats and achieving adjusted EBITDA breakeven. Additionally, Bioptimus announced a partnership with 10X Genomics to launch the Spatial Tissue Embedding Learning Atlas, which aims to profile up to 100,000 patient tissue specimens worldwide, marking a substantial increase in scale for spatial biology initiatives.
Despite these advancements, 10X Genomics faced challenges as ARK Invest sold over 473,000 shares, signaling a shift in investment strategy towards gene-editing platforms. This move has raised concerns about potential reductions in holdings by other institutional investors. Wolfe Research highlighted investor worries regarding a potential decline in demand for spatial proteomics due to AI advancements, such as Microsoft’s GigaTIME model.
On a positive note, Stifel raised its price target for 10X Genomics to $25, maintaining a Buy rating, citing strong adoption of the company’s new Flex Apex product. The competitive landscape in single-cell technology appears favorable for the company. These recent developments underscore the dynamic environment surrounding 10X Genomics as it navigates both opportunities and challenges in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates TXG every month against thousands of alternatives using 100+ financial metrics.It found Siemens Energy (+231.5%) and Sandisk (+189%) before the crowd did. Could TXG be next—or is there a better opportunity in the same space?Don't wait to find out.